Agilent (NYSE:A) initiated with Overweight rating and $100 (18% upside) price target at Wells Fargo.
Avantor (NYSE:AVTR) initiated with Overweight rating and $22 (17% upside) price target at Wells Fargo. Shares down 1% premarket.
Axonics Modulation Technologies (NASDAQ:AXNX) initiated with Buy rating and $38 (41% upside) price target at SunTrust.
Bio-Rad Laboratories (NYSE:BIO) initiated with Overweight rating and $430 (13% upside) price target at Wells Fargo.
BioLife Solutions (NASDAQ:BLFS) initiated with Overweight rating and $23 (44% upside) price target at Stephens.
BioTelemetry (NASDAQ:BEAT) initiated with Buy rating and $58 (21% upside) price target at SunTrust.
Bruker (NASDAQ:BRKR) initiated with Overweight rating and $60 (18% upside) price target at Wells Fargo.
Charles River Labs (NYSE:CRL) initiated with Overweight rating and $180 (16% upside) price target at Wells Fargo.
Cryoport (NASDAQ:CYRX) initiated with Overweight rating and $21 (24% upside) price target at Stephens.
Danaher (NYSE:DHR) initiated with Overweight rating and $170 (9% upside) price target at Wells Fargo. Shares up 1% premarket.
Globus Medical (NYSE:GMED) initiated with Buy rating and $67 (16% upside) price target at SunTrust.
Halozyme Therapeutics (NASDAQ:HALO) initiated with Buy rating and $24 (33% upside) price target at Goldman Sachs.
Hologic (NASDAQ:HOLX) initiated with Equal Weight rating and $57 (9% upside) price target at Wells Fargo.
Horizon Therapeutics (NASDAQ:HZNP) resumed with Neutral rating and $35 (4% downside risk) price target at Goldman.
ICON Public Limited Company (NASDAQ:ICLR) initiated with Equal Weight rating and $180 (7% upside) price target at Wells Fargo.
Illumina (NASDAQ:ILMN) initiated with Underweight rating and $300 (9% downside risk) price target at Wells Fargo.
IRhythm Technologies (NASDAQ:IRTC) initiated with Buy rating and $102 (50% upside) price target at SunTrust.
Kodiak Sciences (NASDAQ:KOD) initiated with Buy rating and $115 (71% upside) price target at Roth Capital.
Labcorp (NYSE:LH) initiated with Overweight rating and $210 (24% upside) price target at Wells Fargo.
Medtronic (NYSE:MDT) initiated with Buy rating and $130 (14% upside) price target at SunTrust.
Mettler-Toledo (NYSE:MTD) initiated with Equal Weight rating and $815 (2% upside) price target at Wells Fargo.
Nevro (NYSE:NVRO) initiated with Buy rating and $132 (9% upside) price target at SunTrust.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.